Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,547 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes Complications Clear all
Completed No phase listed Observational Accepts healthy volunteers

ORWH:SCOR on Sex and Gender Factors Affecting Women's Incontinence

NCT00069368
View directory record Official record
Conditions
Urinary Incontinence, Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
44 Years to 73 Years · Female only
Enrollment
2,161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

NCT07116174
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Xcell Amnio Matrix, Standard of Care (SOC)
Biological · Drug
Lead sponsor
New Horizon Medical Solutions
Network
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fresno, California • San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Avoiding Diabetes After Pregnancy Trial

NCT01923350
View directory record Official record
Conditions
Weight Reduction
Interventions
Weight Reduction Intervention, Weight Reduction Control Arm, Tested for diabetes, Not tested for diabetes
Behavioral
Lead sponsor
Social & Scientific Systems Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

NCT04786340
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions
Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy

NCT02068027
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
Interventions
Clonidine Gel 0.1%, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
23
States / cities
Phoenix, Arizona • Santa Monica, California • Walnut Creek, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes

NCT00678080
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Metformin, Insulin (NPH and Regular)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Jun 10, 2026, 6:15 PM EDT
Withdrawn Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes

NCT00539435
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Intravenous Insulin on cardiac disease in diabetic pts
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

NCT00643760
View directory record Official record
Conditions
Neuropathy, Diabetic
Interventions
Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
90
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional

The Association Between Unprotected Standing, Walking and Wound Healing in Diabetes

NCT02233179
View directory record Official record
Conditions
Diabetic Foot
Interventions
Removable cast walker, Irremovable cast walker
Device
Lead sponsor
University of Arizona
Other
Eligibility
37 Years to 68 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Jun 10, 2026, 6:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional

The IBEP Study: an Intervention for Lifestyle Modification in Women With Gestational Diabetes

NCT01858233
View directory record Official record
Conditions
Gestational Diabetes, Weight Gain During Pregnancy, Weight Loss After Pregnancy
Interventions
Intensive Behavioral Modification
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 4 Interventional Results available

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

NCT00209417
View directory record Official record
Conditions
Renal Insufficiency, Diabetes Mellitus
Interventions
Iodixanol 320-Arm 1, Iopamidol 300-Arm 2
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Jun 10, 2026, 6:15 PM EDT
Active, not recruiting Phase 2 Interventional

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

NCT04929379
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 4 Interventional

Santyl Applications to Diabetic Foot Ulcers

NCT02111291
View directory record Official record
Conditions
Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions
Collagenase SANTYL® Ointment, Hydrogel (if needed) and foam dressing
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Mesa, Arizona • Carlsbad, California • Castro Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT00375960
View directory record Official record
Conditions
Pain, Diabetic Neuropathies
Interventions
V3381, Placebo
Drug
Lead sponsor
Vernalis (R&D) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Walnut Creek, California • Clearwater, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2007 · Synced Jun 10, 2026, 6:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Wound Healing Endpoint and Recurrence

NCT02577120
View directory record Official record
Conditions
Chronic Wound, Burn Wound, Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, Chronic, Wound
Interventions
Epiceram Skin Barrier Function, Vaseline Petroleum Jelly
Device · Biological
Lead sponsor
Sashwati Roy
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 10, 2026, 6:15 PM EDT
Completed No phase listed Observational

Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes

NCT01377688
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Phase 1 Interventional Results available

A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

NCT05510245
View directory record Official record
Conditions
Type 2 Diabetes, Renal Impairment
Interventions
PF-07081532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Tampa, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Results available

Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus

NCT03029702
View directory record Official record
Conditions
Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
Interventions
Insulin, Glyburide, Metformin
Drug
Lead sponsor
Maisa N. Feghali, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jun 10, 2026, 6:15 PM EDT
Terminated Not applicable Interventional Results available

Celliant Socks to Increase Tissue Oxygenation and Complete Wound Closure in Diabetic Foot Wounds

NCT04709419
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Celliant Diabetic Medical Socks, Control (placebo) Medical Socks
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
22 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Magnesium Supplementation in the Second Trimester of Pregnancy to Overweight and Obese Individuals

NCT01510665
View directory record Official record
Conditions
Gestational Diabetes, Obesity
Interventions
Magnesium citrate, Placebo, Dietary modification
Dietary Supplement · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

NCT00915200
View directory record Official record
Conditions
Diabetic Nephropathies, Proteinuria, Oxidative Stress
Interventions
N-acetylcysteine, silibin, high-dose silibin, N-acetylcysteine placebo, silibin placebo
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

NCT00295828
View directory record Official record
Conditions
Iris Neovascularization, Diabetic Retinopathy
Interventions
Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP)
Other · Procedure
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2008 · Synced Jun 10, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

NCT02251067
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
VPI-2690B low dose, VPI-2690B medium dose, Placebo to match VPI-2690B, VPI-2690B high dose
Drug
Lead sponsor
Vascular Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jun 10, 2026, 6:15 PM EDT